● TRB-071, a CD30 agonist antibody designed to activate and expand tissue Tregs and block the CD30L-mediated inflammatory pathway, is progressing through IND-enabling studies ● TRB-051, which is partnered with Lilly, is expected to advance into Phase 2a clinical development in lupus with cutaneous involvement SOUTH SAN FRANCISCO, Calif., June 30, 2026 – TRex Bio, […] The post TRexBio Announces Pipeline Progress, Naming TRB-071 as a CD30 Agonist for Immune-Mediated Diseases and Advancement of Lilly-Partnered TRB-051 appeared first on TrexBio .
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules